Biotech By Adam Feuerstein Natural killer cells, primed with an antibody, induce remissions in patients with advanced lymphoma
Biotech By Adam Feuerstein Bluebird, troubled gene therapy maker, to lay off employees and reduce costs
Exclusive By Matthew Herper Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments
Biotech By Jonathan Wosen When a dire text message interrupted his talk, this doctor’s cancer research became painfully real
Biotech By Adam Feuerstein The biotech scorecard for the second quarter: 21 stock-moving events to watch
Biotech By Megan Molteni In the wake of big patent decision, it’s business as usual for CRISPR therapy developers
Biotech By Adam Feuerstein and Nicholas Florko By narrow margin, FDA advisory panel concludes Amylyx ALS drug hasn’t proven effectiveness
Biotech By Adam Feuerstein and Nicholas Florko Tracking the FDA advisory panel on Amylyx Pharma’s ALS treatment
Biotech By Adam Feuerstein FDA review is critical of data on Amylyx ALS drug, but cites ‘regulatory flexibility’
Biotech By Adam Feuerstein and Matthew Herper Al Sandrock, former top scientist at Biogen, named CEO at Voyager Therapeutics
On Target By Angus Chen After a dry spell for cancer immunotherapy, a new target offers a beacon of hope
Biotech By Jonathan Wosen Illumina sues Guardant Health, saying former employees stole trade secrets to launch liquid biopsy firm
Biotech By Jonathan Wosen Armed with heaps of cash and a veteran team, an upstart looks to disrupt DNA sequencing
Biotech By Adam Feuerstein Combination treatment from Nektar and Bristol Myers Squibb fails to benefit patients with melanoma, study shows
Biotech By Isabella Cueto He was creating the building blocks for drug developers worldwide. Then Russia started to bomb Kyiv
Biotech By Adam Feuerstein What to know about Amylyx’s ALS drug and a highly anticipated advisory panel meeting
Matt's Take By Matthew Herper Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough
Biotech By Adam Feuerstein A key study of Gilead’s breast cancer drug meets goal, but withheld data raise doubts
Biotech By Adam Feuerstein With cash running short, Bluebird Bio and its gene therapies face uncertain future
Biotech By Jonathan Wosen ‘Something is off here’: Black biotech entrepreneurs still struggle for funding as the industry pledges to diversify
Biotech By Adam Feuerstein and Damian Garde With Aduhelm in limbo, Biogen starts laying off employees
Biotech By Damian Garde Awaiting ‘definitive’ Alzheimer’s drug data, Roche and Genentech launch ambitious new study
Adam's Take By Adam Feuerstein Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent
Biotech By Ryan Cross — The Boston Globe Vesalius Therapeutics launches to develop treatments for common diseases